Andrea Corona Altimmunes GLP-1 drug shows positive results for alcohol use disorder On Tuesday, Altimmune announced topline data from their Phase 2 RECLAIM trial showing that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced the number of heavy drinking days compared to placebo in patients with moderate to severe alcohol use disorder
Important medical and regulatory considerations Peptides such as BPC-157 and CJC-1295/Ipamorelin are not standard first-line therapies
Mol Med (2020) 26(1):92
Key Specifications: Best peptide lip serum Dr
Testing Round 2 - Purity Analysis: The company states this screens for contaminants including heavy metals (lead, mercury, arsenic, cadmium), microbial pathogens (bacteria, yeast, mold), and residual solvents from manufacturing processes
Common Mistakes When Using a Retatrutide Calculator Even with a retatrutide calculator, mistakes can happen if you are not careful